127 results on '"Vranic, Ivana"'
Search Results
2. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
3. Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
4. Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
5. Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis
6. Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure
7. Characterization of Cardiac Electrophysiology Including ECG-Analysis
8. Pharmacodynamic Evaluation: Cardiovascular Methodologies
9. Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
10. Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial
11. Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial
12. S1194 Tofacitinib for the Treatment of Ulcerative Colitis: Up to 9.2 Years of Safety Data From the Global Clinical Program
13. Characterization of Cardiac Electrophysiology Including ECG-Analysis
14. Abstract 12790: Classification of the Different Types of Hypertrophic Cardiomyopathy Responsible for Advanced Heart Failure: From Clinical, Morphofunctional Characteristics to Prognosis and Potential New Therapies
15. Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
16. Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib
17. Cartografia, arte e potere tra Riforma e Controriforma: Il Palazzo Farnese a Caprarola. Alessandro Ricci and Carlotta Bilardi. Modena: Franco Cosmi Panini Editore, 2020. 218 pp. €28.
18. Paintings on Stone: Science and the Sacred 1530–1800. Judith W. Mann, ed. Munich: Hirmer Publishers, 2022. 320 pp. $50.
19. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial
20. Enhanced Publication Content for the manuscript: Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial
21. Plain language summary for the manuscript: Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial
22. sj-docx-1-tab-10.1177_1759720X221149965 – Supplemental material for Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib
23. Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors
24. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
25. Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme
26. A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease
27. Electrocardiographic appearance of aortic stenosis before and after aortic valve replacement
28. Pharmacodynamic Evaluation: Cardiovascular Methodologies
29. Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib
30. RA-MAP, molecular immunological landscapes in early rheumatoid arthritis and healthy vaccine recipients
31. Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme.
32. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial.
33. Enhanced Publication Content for the manuscript: Risk of major adverse cardiovascular events with tofacitinib vs tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
34. Plain language summary for the manuscript: Risk of major adverse cardiovascular events with tofacitinib vs tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
35. 716 PREGNANCY OUTCOMES AFTER MATERNAL OR PATERNAL EXPOSURE IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAM
36. Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
37. Additional file 2 of Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial
38. Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26–52, including a treatment switch from reference ADL to PF-06410293
39. Making and remaking Renaissance sculpture : the terracotta groups (1460–1560)
40. Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
41. A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease
42. Sudden Cardiac Death: Predictors, Prevalence and Clinical Perspectives
43. Concept of initial literacy in preschool children
44. Visibility of sculpted matter and form : Michelangelo’s Rondanini Pietà and the ontological nature of sculpture
45. EFFICACY AND SAFETY OF SUBCUTANEOUS VERSUS INTRAVENOUS TOCILIZUMAB IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS: 49 WEEK SUMMACTA DATA
46. SUMMACTA: A Randomized, Double-Blind, Parallel Group Study of the Safety and Efficacy of Tocilizumab SC versus Tocilizumab IV, in Combination with Traditional DMARDs in Patients with Moderate to Severe RA
47. O22. Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab In Combination with Traditional Dmards in Patients with Rheumatoid Arthritis: 49 Week Summacta Data
48. 10.5937/comman1431039v = Metaphor, personification and hyperbole in pharmaceutical products advertisements
49. Signaling prodromes of sudden cardiac death
50. Phase 2 Randomized Study of CP-690,550, an Oral Janus Kinase Inhibitor, in Active Crohn's Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.